Antagonism of interferon beta on interferon gamma: inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients
Authors:
- 1 September 1995
- journal article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 1 (1_suppl) , S5-S11
Abstract
Interferon gamma (IFN-γ acts as a mediator of multiple sclerosis (MS) exacerbations through a number of biological effects, such as induction of major histocompatibility class II complexes (MHC-II), macrophage activation and potentiation of tumor necrosis factor (TNF-α). The clinical efficacy of interferon beta (IFN-β) therapy in reducing exacerbations of relapsing–remitting MS has been related to antagonistic effects on various activities of IFN-y, including MHC-II gene induction. However, there is no model to explain such antagonistic effects of IFN-β and IFN-y, and the two cytokines are also known to act synergistically against viruses and in the induction of MHC-I. We show that IFN-β does inhibit an immediate molecular event of IFN-y, namely activation and DNA binding of the transcription factor Stat I. We propose a model of direct interference of the IFN-y and IFN-a,β signal transduction pathways accounting for antagonistic effects on some genes, which in turn activate MHC-II transcription, as well as for synergistic effects on other genes. In addition, study of MS patients treated with natural IFN-β shows that IFN-β significantly reduces serum levels of IFN-y while increasing IL-4, strongly suggesting that IFN-β also controls the relative activation of THI- and TH2-type T lymphocytes.Keywords
This publication has 47 references indexed in Scilit:
- Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN‐alpha and IFN‐beta.The EMBO Journal, 1994
- Ligand‐induced IFN gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91).The EMBO Journal, 1994
- Induction by interleukin‐6 of interferon regulatory factor 1 (IRF‐1) gene expression through the palindromic interferon response element pIRE and cell type‐dependent control of IRF‐1 binding to DNA.The EMBO Journal, 1994
- Antisense oligonucleotides specific for regulatory factor RFX‐1 inhibit inducible but not constitutive expression of all major histocompatibility complex class II genesEuropean Journal of Immunology, 1993
- Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon‐alpha and ‐gamma signal transduction pathways.The EMBO Journal, 1993
- Contrasting effects of alpha, beta, and gamma interferons on nonspecific suppressor function in multiple sclerosisAnnals of Neurology, 1992
- Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitroAnnals of Neurology, 1988
- Clinical Use of Interferons in the Treatment of Malignant Brain Tumors1988
- Identity between human interferon-γ and “macrophage-activating factor” produced by human T lymphocytesEuropean Journal of Immunology, 1986
- Differential regulation of HLA‐DR mRNAs and cell surface antigens by interferon.The EMBO Journal, 1983